NCT05401786

Who might be able to join this trial:

• You have been diagnosed with advanced non-small cell lung cancer (NSCLC) that has come back or continued to spread, regardless of the specific type of NSCLC.
• You are willing and able to sign a consent form agreeing to take part in the trial.
• You still have at least one area of cancer that can be measured on a scan after receiving the targeted radiation treatment used in this study.
• You are willing to have a tissue sample (biopsy) taken from a tumor before treatment, and to have a second biopsy taken from a non-irradiated tumor after treatment begins.
• You are generally healthy and able to carry out daily activities with little or no limitation (measured by a standard scale called ECOG, scored 0 or 1).
• Your lung cancer has spread to other parts of the body (Stage IV) and you have already been treated with a type of immunotherapy called PD-(L)1 blockade (checkpoint inhibitor).
• You have at least 2 separate areas of cancer — one that can receive targeted radiation and another that can be biopsied and measured on scans.
• Your liver, kidneys, and other organs are functioning well enough, confirmed by blood tests taken within 14 days of starting treatment.
• If you can become pregnant, you have tested negative for pregnancy within 72 hours before your first dose of study medication.
• If you can become pregnant, you are willing to use 2 forms of contraception, or are surgically sterile, or abstain from sex throughout the study and for 6 months after the last dose.
• If you are male, you agree to use adequate contraception from your first dose until 6 months after your last dose.

Who may not be able to join:

• Your lung cancer has a specific non-smoking-related gene mutation (such as EGFR, ALK, RET, or ROS1) that can be targeted with specific drugs (confirm with trial site for smoking-related mutations such as KRAS or BRAF).
• You are currently taking part in another clinical trial or have used an experimental drug or device within the last 4 weeks.
• You are still experiencing significant side effects from a previous cancer treatment that have not returned to a mild or baseline level (with some exceptions — confirm with trial site).
• You have had major surgery within 14 days before the start of the study, or have not fully recovered from any previous surgery.
• You have had high-dose (radical) radiation to any tumor site within the last 3 months.
• You have previously been treated with certain other types of immunotherapy drugs that target the immune system in ways other than PD-(L)1 blockade (for example, anti-CTLA-4 or anti-CD137 drugs).
• You have brain or nervous system cancer spread (metastases) that are causing symptoms, are larger than 2 cm, have significant swelling around them on an MRI scan, or have spread to the lining of the brain.
• You have another active cancer that is growing or currently being treated.
• You have a serious autoimmune disease (where the immune system attacks the body) that requires ongoing treatment with steroids or immune-suppressing medications (confirm with trial site, as some exceptions may apply).
• You have active or symptomatic lung inflammation (interstitial lung disease or pneumonitis) that is not caused by infection.
• You have an active infection that requires treatment through your bloodstream (e.g., IV antibiotics).

Important: Always verify eligibility with the trial site directly before applying.